Fecal Calprotectin Test Market To Reach $9.55 Billion By 2030

Fecal Calprotectin Test Market Growth & Trends

The global fecal calprotectin test market size is expected to reach USD 9.55 billion by 2030, registering a CAGR of 11.2% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing incidence of colorectal cancer, which has become one of the most common forms of cancer worldwide, is the major factor for the market growth. As healthcare systems continue to prioritize early detection to improve patient outcomes and reduce healthcare costs, fecal calprotectin testing has emerged as an essential tool for identifying inflammation in the gastrointestinal tract, which can be an early indicator of colorectal cancer. The test, which measures the concentration of calprotectin in stool samples, provides healthcare professionals with valuable information to determine whether further diagnostic procedures, such as colonoscopies, are necessary. This non-invasive approach offers a significant advantage over traditional diagnostic methods, making it a preferred option for both patients and healthcare providers.

Another significant factor contributing to the growth of the fecal calprotectin test market is the increasing prevalence of inflammatory bowel diseases, including Crohn’s disease and ulcerative colitis. These chronic conditions, which cause inflammation in the digestive tract, require ongoing monitoring and management. Fecal calprotectin tests plays a crucial role in assessing disease activity and monitoring treatment response in patients with IBD. As the global incidence of IBD rises, particularly in developed countries, the demand for reliable, non-invasive diagnostic tools like fecal calprotectin tests is expected to increase. The ability to monitor disease progression and flare-ups without the need for invasive procedures is a key advantage that is driving the adoption of this test among healthcare providers and patients.

The growing awareness of the importance of preventive healthcare is also a significant factor driving the market. Governments, healthcare organizations, and advocacy groups are increasingly focusing on the early detection of colorectal cancer and other gastrointestinal disorders. National screening programs for colorectal cancer are being implemented in many countries, and fecal calprotectin tests are often included as part of these programs. As more individuals undergo routine screening, the demand for fecal calprotectin test is expected to rise. Additionally, as the general population becomes more aware of the risks associated with colorectal cancer and IBD, there is a growing demand for diagnostic tests that can detect these conditions early, further fueling market growth.

Technological advancements in fecal calprotectin test is also contributing to the market’s expansion. The development of more accurate, faster, and user-friendly testing devices has made fecal calprotectin tests more accessible and efficient. Innovations such as automated analyzers and home testing kits have made it easier for both healthcare providers and patients to use this diagnostic tool. Automated systems, in particular, have streamlined the testing process, allowing for higher throughput in clinical laboratories and improving the efficiency of testing. Home test kits, on the other hand, provide patients with a convenient way to monitor their gastrointestinal health in the comfort of their own homes. These advancements are helping to drive the adoption of fecal calprotectin tests, particularly in regions where healthcare access may be limited or where patients prefer to manage their health independently.

Key players in the market are focusing on technological advancements, such as the development of user-friendly, automated systems that streamline the testing process and improve throughput in clinical settings. Additionally, there is a growing trend toward home-based testing solutions, with companies like BIOHIT Healthcare introducing self-test kits that allow patients to monitor their condition remotely. The market is also witnessing an increase in partnerships, collaborations, and acquisitions as companies seek to expand their product portfolios and strengthen their market presence. Competitive strategies are heavily influenced by the need to improve test sensitivity, reduce costs, and enhance patient convenience, with companies continuously working to differentiate their products in an increasingly crowded market.

 Request a free sample copy or view report summary: Fecal Calprotectin Test Market Report

Fecal Calprotectin Test Market Report Highlights

• Based on assay, enzyme-linked immunosorbent assay accounted for the largest revenue share of 66.4% in 2024. One of the primary reasons for its dominance is its high sensitivity and specificity, which allows for accurate detection of inflammation associated with gastrointestinal disorders such as inflammatory bowel diseases (IBD) and colorectal cancer

• Based on application, inflammatory bowel disease dominated the market and accounted for the largest share of 66.0% in 2024.This can be attributed to the increasing prevalence of the disease in emerging as well as developed nations

• Based on end-use, the hospitals and clinics segment dominated the end use segments with the largest market share of 54.7% in 2024. The segment dominance is attributed to large patient volumes being tested in hospitals

• North America dominated the global market due to the presence of a large number of major market players. North America has a high prevalence of IBS and other gastric diseases. Furthermore, well-developed healthcare infrastructure fuels regional market growth

• Asia Pacific is expected to witness the fastest growth with a CAGR of 12.7% over the forecast period from 2025 to 2030, due to the development of healthcare facilities across emerging markets. Furthermore, increasing focus on preventive routine testing is also supporting the market growth

Fecal Calprotectin Test Market Segmentation

Grand View Research has segmented the fecal calprotectin test market based on assay, application, end-use, and region:

Fecal Calprotectin Test Assay Outlook (Revenue, USD Million, 2018 - 2030)

• Enzyme-linked Immunosorbent Assay

• Enzyme Fluroimmunoassay

• Quantitative Immunochromatography

Fecal Calprotectin Test Application Outlook (Revenue, USD Million, 2018 - 2030)

• Inflammatory Bowel Disease

• Colorectal Cancer

• Others

Fecal Calprotectin Test End-use Outlook (Revenue, USD Million, 2018 - 2030)

• Hospitals And Clinics

• Diagnostic Laboratories

• Academic And Research Institutes

Fecal Calprotectin Test Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • UK

  • Germany

  • France

  • Italy

  • Spain

  • Sweden

  • Denmark

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa

  • Saudi Arabia

  • South Africa

  • UAE

  • Kuwait

List of Key Players in the Fecal Calprotectin Test Market

• Epitope Diagnostics Inc.

• Hycult Biotech

• Actim

• Eagle Biosciences, Inc.

• OPERON

• Svar Life Science

• BÜHLMANN

• DRG International Inc

• ALPCO

• Diazyme Laboratories